Halo Therapeutics

A trial of an experimental compound to counteract muscle inflammation and scarring in Duchenne MD resumes, after an interruption to complete a dog safety study

posted on June 17, 2014 - 12:38pm
Update (July 3, 2014): Akashi says the HT-100 main trial is now closed; the extension study is open to those who have already participated in the main trial.

An MDA Venture Philanthropy grant of $500,000 to Halo Therapeutics will support the development of HT-100, an experimental drug for Duchenne muscular dystrophy

posted on November 14, 2013 - 7:00am
Update (June 12, 2014):  In a June 12, 2014, announcement, Halo Therapeutics said that it has resumed testing of HT-100, an experimental oral drug intended to reduce scar formation and inflammation and promote healthy muscle regeneration in DMD. The company will now continue to enroll and dose DMD ptients in its ongoing clinical trial and extension study.

30-person trial will test the safety, tolerability and pharmacokinetics of the experimental drug HT-100 in boys with Duchenne muscular dystrophy

posted on July 30, 2013 - 1:51pm
Update (Jan. 6, 2014): In a Dec. 23, 2013, announcement, Halo said the U.S. Food and Drug Administration (FDA) had placed this trial on "clinical hold" because of some adverse events that occurred in dogs being treated with HT-100. No further dosing of patients will occur until this issue has been resolved.